BSX Earnings Preview: Boston Scientific Q1 2026 on April 22

Boston Scientific Corporation (BSX) reports first-quarter earnings on April 22, 2026, after market close. The medical device giant faces investor scrutiny as it reports results amid a challenging market environment. Analysts expect earnings per share of $0.80 and revenue of $5.17 billion. The stock has declined 5% this week, trading at $60.99. Meyka AI rates BSX with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Understanding what to watch helps investors prepare for potential market moves.

Earnings Estimates and Historical Performance

Analysts expect Boston Scientific to deliver $0.80 earnings per share and $5.17 billion in revenue for the upcoming quarter. These estimates represent a modest increase from recent quarters, reflecting steady operational performance. Looking at the last four quarters, the company has shown consistent earnings growth. In February 2026, BSX beat EPS estimates of $0.78 with actual earnings of $0.80, while revenue came in at $5.286 billion versus the $5.281 billion estimate. This pattern of beating expectations suggests management executes well on guidance.

Recent Quarter Trends

The company’s earnings trajectory shows improvement over the past year. In July 2025, BSX reported $0.75 EPS against a $0.725 estimate, beating by $0.025 per share. Revenue reached $5.061 billion versus the $4.893 billion estimate. Earlier in April 2025, the company again beat with $0.75 EPS on a $0.673 estimate. This consistent outperformance indicates strong operational discipline and conservative guidance practices.

Revenue Momentum

Revenue growth has accelerated meaningfully. The company generated $5.286 billion in the most recent quarter, up from $5.061 billion in the prior quarter. This represents sequential growth of approximately 4.4%, suggesting healthy demand across Boston Scientific’s three business segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The $5.17 billion estimate for the upcoming quarter sits between recent results, indicating analyst expectations for continued momentum.

What Investors Should Watch

Boston Scientific’s earnings call will focus on segment performance, margin expansion, and guidance for the full year. With 53,000 employees globally, the company operates in competitive medical device markets where innovation drives growth. Investors should monitor commentary on product launches, pricing power, and international market conditions.

Segment Performance Breakdown

The MedSurg segment, which includes gastrointestinal and pulmonary devices, typically represents the largest revenue contributor. Rhythm and Neuro focuses on cardiac and pain management solutions, while Cardiovascular handles interventional cardiology and structural heart products. Management will likely discuss growth rates within each segment and any competitive pressures. Watch for commentary on the company’s drug-eluting stent systems and ablation catheter sales, which are key growth drivers.

Margin and Cash Flow Metrics

Operating margins matter significantly for medical device companies. Boston Scientific reported a gross profit margin of 69% trailing twelve months, indicating strong pricing and manufacturing efficiency. Free cash flow per share reached $2.44, supporting the company’s investment in research and development. Analysts will scrutinize whether margins remain stable or face pressure from manufacturing costs or competitive pricing. The company’s R&D spending represents 10.2% of revenue, critical for maintaining competitive advantages in device innovation.

Guidance and Forward Outlook

Management guidance for full-year 2026 will heavily influence stock movement. With the stock down 36% year-to-date, investors seek reassurance about growth prospects. The company’s debt-to-equity ratio of 0.51 provides flexibility for acquisitions or increased shareholder returns. Watch for any commentary on M&A activity, as Boston Scientific has historically grown through strategic acquisitions in the medical device space.

Technical and Valuation Context

Boston Scientific trades at a price-to-earnings ratio of 31.4, elevated compared to historical averages but reasonable for a healthcare company with consistent earnings growth. The stock’s 52-week range spans from $60.59 to $109.50, showing significant volatility. Current technical indicators suggest oversold conditions, with the Relative Strength Index at 33.74, indicating potential for a bounce if earnings meet expectations.

Valuation Metrics

The company’s price-to-sales ratio of 4.54 reflects investor expectations for continued revenue growth. Enterprise value to EBITDA stands at 20.5x, suggesting the market prices in moderate growth assumptions. With a market cap of $90.64 billion and 1.49 billion shares outstanding, BSX remains a large-cap healthcare leader. The current valuation leaves room for upside if the company beats estimates and raises guidance, or downside if management disappoints.

Technical Setup

The stock’s 50-day moving average sits at $69.94, while the 200-day average is $92.16. This positioning below both key moving averages suggests a downtrend that could reverse on positive earnings. Volume has averaged 16.4 million shares daily, providing good liquidity for institutional investors. The Average True Range of $2.05 indicates typical daily price swings of 3-4%, so earnings could easily drive a 5-10% move in either direction.

Analyst Consensus and Beat Probability

Wall Street consensus strongly favors Boston Scientific, with 24 buy ratings and only 1 hold rating among analysts covering the stock. No sell ratings exist, reflecting broad confidence in the company’s business model and growth prospects. This unanimous bullish stance suggests analysts expect the company to beat current estimates, based on historical execution patterns.

Historical Beat Pattern

Boston Scientific has beaten EPS estimates in three of the last four quarters, with an average beat of $0.04 per share. The company missed revenue estimates only once in the past year, suggesting management guides conservatively on earnings but more accurately on revenue. This pattern indicates a 75% probability the company beats the $0.80 EPS estimate. If the company delivers $0.82-$0.84 EPS, the stock could rally 3-5% immediately following the announcement.

Meyka AI Grade Implications

The B+ grade reflects balanced risk-reward dynamics. The grade incorporates strong return on assets (6.6%) and return on equity (12.5%), indicating efficient capital deployment. However, the elevated PE ratio and debt levels temper enthusiasm. The grade suggests BSX offers solid growth potential with manageable downside risk, making it suitable for growth-oriented investors with moderate risk tolerance. Earnings that confirm guidance should support the B+ rating.

Final Thoughts

Boston Scientific enters earnings season with strong momentum from recent quarters and unanimous analyst support. The $0.80 EPS and $5.17 billion revenue estimates appear achievable based on historical execution, with a 75% probability of beating earnings. The stock’s 36% year-to-date decline creates a compelling risk-reward setup for investors. Watch for segment growth rates, margin commentary, and full-year guidance to determine if the recent selloff represents a buying opportunity or signals deeper concerns. The B+ Meyka AI grade supports a constructive outlook, though valuation at 31x earnings leaves limited room for disappointment.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.